Replication-defective viruses as vaccines and vaccine vectors

被引:148
作者
Dudek, T
Knipe, DM
机构
[1] Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA
[2] Harvard Univ, Sch Publ Hlth, Program Biol Sci & Publ Hlth, Boston, MA 02115 USA
关键词
vaccine; virus; replication-defective mutant; nonreplicating; vector;
D O I
10.1016/j.virol.2005.09.020
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The classical viral vaccine approaches using inactivated virus or live-attenuated virus have not been successful for some viruses, such as human immunodeficiency virus or herpes simplex virus. Therefore, new types of vaccines are needed to combat these infections. Replication defective mutant viruses are defective for one or more functions that are essential for viral genome replication or synthesis and assembly of viral particles. These viruses are propagated in complementing cell lines expressing the missing gene product; however, in normal cells, they express viral gene products but do not replicate to form progeny virions. As vaccines, these mutant viruses have advantages of both classical types of viral vaccines in being as safe as inactivated virus but expressing viral antigens inside infected cells so that MHC class I and class II presentation can occur efficiently. Replication-defective viruses have served both as vaccines for the virus itself and as a vector for the expression of heterologous antigens. The potential advantages and disadvantages of these vaccines are discussed as well as contrasting them with single-cycle mutant virus vaccines and replicon/amplicon versions of vaccines. Replication-defective viruses have also served as important probes of the host immune response in helping to define the importance of the first round of infected cells in the host immune response, the mechanisms of activation of innate immune response, and the role of the complement pathway in humoral immune responses to viruses. (c) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:230 / 239
页数:10
相关论文
共 92 条
  • [1] HIV-1 RECOMBINANT POXVIRUS VACCINE INDUCES CROSS-PROTECTION AGAINST HIV-2 CHALLENGE IN RHESUS MACAQUES
    ABIMIKU, AG
    FRANCHINI, G
    TARTAGLIA, J
    ALDRICH, K
    MYAGKIKH, M
    MARKHAM, PD
    CHONG, PL
    KLEIN, M
    KIENY, MP
    PAOLETTI, E
    GALLO, RC
    ROBERTGUROFF, M
    [J]. NATURE MEDICINE, 1995, 1 (04) : 321 - 329
  • [2] Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine
    Amara, RR
    Villinger, F
    Altman, JD
    Lydy, SL
    O'Neil, SP
    Staprans, SI
    Montefiori, DC
    Xu, Y
    Herndon, JG
    Wyatt, LS
    Candido, MA
    Kozyr, NL
    Earl, PL
    Smith, JM
    Ma, HL
    Grimm, BD
    Hulsey, ML
    Miller, J
    McClure, HM
    McNicholl, JM
    Moss, B
    Robinson, HL
    [J]. SCIENCE, 2001, 292 (5514) : 69 - 74
  • [3] Outcome of immunization of cynomolgus monkeys with recombinant Semliki Forest virus encoding human immunodeficiency virus type 1 envelope protein and challenge with a high dose of SHIV-4 virus
    Berglund, P
    QuesadaRolander, M
    Putkonen, P
    Biberfeld, G
    Thorstensson, R
    Liljestrom, P
    [J]. AIDS RESEARCH AND HUMAN RETROVIRUSES, 1997, 13 (17) : 1487 - 1495
  • [4] A Genetically inactivated herpes simplex virus type 2 (HSV-2) vaccine provides effective protection against primary and recurrent HSV-2 disease
    Boursnell, MEG
    Entwisle, C
    Blakeley, D
    Roberts, C
    Duncan, IA
    Chisholm, SE
    Martin, GM
    Jennings, R
    Challanain, DN
    Sobek, I
    Inglis, SC
    McLean, CS
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1997, 175 (01) : 16 - 25
  • [5] Herpes simplex virus vectors elicit durable immune responses in the presence of preexisting host immunity
    Brockman, MA
    Knipe, DM
    [J]. JOURNAL OF VIROLOGY, 2002, 76 (08) : 3678 - 3687
  • [6] Complete, long-lasting protection against malaria of mice primed and boosted with two distinct viral vectors expressing the same plasmodial antigen
    Bruña-Romera, O
    González-Aseguinolaza, G
    Hafalla, JCR
    Tsuji, M
    Nussenzweig, RS
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (20) : 11491 - 11496
  • [7] Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection - Two randomized controlled trials
    Corey, L
    Langenberg, AGM
    Ashley, R
    Sekulovich, RE
    Izu, AE
    Douglas, JM
    Handsfield, HH
    Warren, T
    Marr, L
    Tyring, S
    DiCarlo, R
    Adimora, AA
    Leone, P
    Dekker, CL
    Burke, RL
    Leong, WP
    Straus, SE
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (04): : 331 - 340
  • [8] COULIBALY S, 2005, VIROLOGY 0729
  • [9] Construction, phenotypic analysis, and immunogenicity of a UL5/UL29 double deletion mutant of herpes simplex virus 2
    Da Costa, X
    Kramer, MF
    Zhu, J
    Brockman, MA
    Knipe, DM
    [J]. JOURNAL OF VIROLOGY, 2000, 74 (17) : 7963 - 7971
  • [10] Immunization against genital herpes with a vaccine virus that has defects in productive and latent infection
    Da Costa, XJ
    Jones, CA
    Knipe, DM
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (12) : 6994 - 6998